Julai 2022: Menurut penyelidikan terbaru yang dijalankan oleh Emergen Research, pasaran global untuk terapi sel T CAR mencapai saiz USD 1.29 bilion pada 2021 dan dijangka mencatatkan CAGR hasil sebanyak 24.9 peratus sepanjang tempoh ramalan. Peningkatan kejadian kanser di seluruh dunia serta kadar kematian yang semakin meningkat disebabkan oleh kanser dijangka menjadi pemacu utama pertumbuhan pendapatan dalam pasaran terapi sel CAR-T global sepanjang tempoh ramalan. Perkembangan aktiviti percubaan klinikal pada kadar yang pantas, percambahan penggabungan dan pengambilalihan, dan tarikan tawaran awam permulaan adalah semua faktor yang menyumbang kepada pertumbuhan hasil dalam pasaran terapi sel T CAR global.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Terapi Sel T KERETA market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Terapi Sel T KERETA market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Penemuan penting tambahan daripada laporan menunjukkan bahawa
In 2021, the segment of diffuse large B-cell limfoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with terapi sel T reseptor antigen chimeric, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell limfoma bukan Hodgkin who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Syarikat-syarikat utama yang kini beroperasi dalam pasaran disiasat lebih lanjut dalam laporan ini, begitu juga dengan profil syarikat, portfolio produk, strategi pengembangan dan pakatan strategik mereka. Beberapa contoh jenis pakatan ini termasuk penggabungan dan pengambilalihan, kerjasama dan usaha sama. Di samping itu, ia menyediakan sorotan tentang pencapaian dan kedudukan kewangan syarikat, serta pandangan tentang jangkauan pasaran dan kedudukan global syarikat.
Syarikat yang berprofil dalam pasaran Terapi Sel T CAR global:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Syarikat Daiichi Sankyo, Limited, Syarikat Bristol-Myers Squibb, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., dan Eli Lilly and Company .
Baca lebih lanjut mengenai laporan pasaran CAR T-Cell Therapy global di: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
